Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This post-market clinical follow-up (PMCF) study aims to confirm the safety and performance of the GLOW400 surgical microscope accessory when used in conjunction with the ARveo8x surgical microscope. The study evaluates fluorescence visualization and image quality during standard surgical procedures in neurosurgery. It is a non-interventional, observational study conducted in routine care settings across multiple European sites.
The IMED-GLOW400 study is a prospective, observational, non-interventional clinical investigation conducted in the European Economic Area and Switzerland. It involves the use of the GLOW400 accessory, which digitally enhances fluorescence signals during neurosurgery, providing improved anatomical visualization and contrast. The study compares GLOW400 with the benchmark FL400 optical filter system.
The primary objective is to confirm the image quality and fluorescence visualization performance of GLOW400. Secondary objectives include validating product claims and assessing user experience and safety. An exploratory objective evaluates the extent of tumor resection using volumetric analysis of pre- and post-operative MRI scans.
Data will be collected through structured questionnaires, histopathology confirmation, optional resection forms, and intraoperative video recordings. The study will enroll 37 patients, with at least 29 complete datasets required for analysis. The duration of the study is estimated at 5 to 6 months, with each patient participating only during the surgical procedure.
The study complies with ISO 14155:2020, GDPR, and the Declaration of Helsinki. Ethics Committee approval and informed consent are mandatory prior to enrollment. No additional procedures beyond standard of care are introduced, and risks are limited to those associated with routine surgical practice.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| GLOW400 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| GLOW400 is a digital surgical microscope accessory used in fluorescent visualization of suspected grade III or IV gliomas during neurosurgery. | Device | The digital surgical microscope accessory GLOW400 is using the optical excitation and emission filtering of the FL400. The FL400 provides an illumination filter (380nm - 430nm) which when engaged into the light source path of the surgical operating microscope provides, via a light guide, a fluorescence excitation light system used in conjunction with an approved tumor-selective substance (fluorophore) (e.g. Protoporphyrin IX (PpIX) which is resulting of the metabolization of 5-ALA (5 - aminolaevulinic acid)) for tissue characterization in the open neurosurgery field. PpIX is strongly fluorescent with a peak at λ=635 nm as red-violet after excitation with blue light (λ=380-410 nm). The digital surgical microscope accessory GLOW400 is using the optical excitation and emission filtering of the FL400. The fluorescence signal visualized depicts the distribution of the dye in the patient's tissues during the surgical procedure. |
| Measure | Description | Time Frame |
|---|---|---|
| Flourescence visibility | Performance will be evaluated using Questionnaire, a structured Likert-scale survey completed by the operating surgeon during and after surgery. The questionnaire assesses:
Each item is rated on a 5-point Likert scale:
Higher scores indicate better performance. The outcome is considered acceptable if all ratings are ≥3 (Sufficient or better). | Periprocedural |
| Image quality | Performance will be evaluated using Questionnaire, a structured Likert-scale survey completed by the operating surgeon during and after surgery. The questionnaire assesses::
Each item is rated on a 5-point Likert scale:
Higher scores indicate better performance. The outcome is considered acceptable if all ratings are ≥3 (Sufficient or better). | Periprocedural |
| Anatomy of the brain, including Vessels (GLOW400 Anatomy only) | Performance will be evaluated using Questionnaire, a structured Likert-scale survey completed by the operating surgeon during and after surgery. The questionnaire assesses:
Each item is rated on a 5-point Likert scale:
Higher scores indicate better performance. The outcome is considered acceptable if all ratings are ≥3 (Sufficient or better). | Periprocedural |
| Measure | Description | Time Frame |
|---|---|---|
| The secondary objectives of this Post-Market Clinical Follow-up (PMCF) study are to assess the continued safety of the device. | Safety will be evaluated using Questionnaire B, completed postoperatively by the surgical team. It captures:
Responses are binary:
Lower scores (2 = No) indicate better safety outcomes. The outcome is acceptable if no safety events are reported. |
| Measure | Description | Time Frame |
|---|---|---|
| Assessment of the extent of tumor resection | The extent of tumor resection will be evaluated using volumetric analysis. The volumetric measurement will be carried out by a neuroradiologist. Precise three-dimensional (3D) rendering and analysis of pre-operative and post-operative MRI images, facilitating accurate assessment of residual tumor volume. Radiology reports include: • Residual tumor percentage %. Based on the residual tumor percentage, the appropriate category will be selected (4):
|
Candidates for the for the IMED-GLOW400 Study must be appropriate patients for surgical interventions with suspected intracranial high-grade glioma evidenced by preoperative imaging modalities and have to fulfil all of the following inclusion criteria to be eligible for the recruitment of the study.
Inclusion Criteria
Note for Switzerland only:
Enrollment via legal representative is not permitted. Therefore, only patients who are capable of providing informed consent themselves will be eligible for inclusion in Switzerland.
Exclusion Criteria
Not provided
Not provided
Not provided
Patient population will include patients with suspected grade III or IV gliomas requiring surgical intervention, and who meet the Inclusion/Exclusion Criteria for the IMED-GLOW400 Study.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Daniela Leal | Contact | +41793741989 | daniela.leal@leica-microsystems.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Unidade Local de Saúde de São João | Porto | Portugal |
IPD used in the results publication.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Postoperatively |
| Postoperatively |
| University Hospital Basel | Basel | Switzerland |
|
| ID | Term |
|---|---|
| D005910 | Glioma |
| D005909 | Glioblastoma |
| ID | Term |
|---|---|
| D018302 | Neoplasms, Neuroepithelial |
| D017599 | Neuroectodermal Tumors |
| D009373 | Neoplasms, Germ Cell and Embryonal |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009380 | Neoplasms, Nerve Tissue |
| D001254 | Astrocytoma |
Not provided
Not provided